Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study.

Abstract excerpt

INTRODUCTION: In this study, we aimed to evaluate the efficacy and safety of the combination therapy with chemotherapy and anlotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations who exhibit primary resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). METHODS: Clinical data were collected from patients with advanced NSCLC harboring EGFR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Carcinoma, Non-Small-Cell Lung